2-Tert-butyl-3-fluoro-5-(trifluoromethyl)pyridine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-Tert-butyl-3-fluoro-5-(trifluoromethyl)pyridine
• 英文别名: 2-tert-butyl-3-fluoro-5-(trifluoromethyl)pyridine
• 化学式: C₁₀H₁₁F₄N
• 分子量: 221.19
• InChiKey: QLQLBVCOMSWYOZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• AGENTS FOR TREATING PAIN AND USES THEREOF
  申请人：ABBVIE INC.

  公开号：US20140171423A1

  公开（公告）日：2014-06-19

  This invention relates to: (a) compounds and salts thereof that, inter alia, treat pain; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.

  这项发明涉及：(a) 化合物及其盐，用于治疗疼痛等症状；(b) 用于制备这些化合物和盐的中间体；(c) 包括这些化合物和盐的组合物；(d) 制备这些中间体、化合物、盐和组合物的方法；(e) 使用这些化合物、盐和组合物的方法；以及(f) 包括这些化合物、盐和组合物的试剂盒。
• METHOD FOR PRODUCING BENZIMIDAZOLE DERIVATIVE
  申请人：Sumitomo Dainippon Pharma Co., Ltd.

  公开号：US20200071295A1

  公开（公告）日：2020-03-05

  The present invention relates to a process to prepare a benzimidazole derivative useful as a medicament, an intermediate for preparing the medicament, and a process to prepare the intermediate.

  本发明涉及一种制备苯并咪唑衍生物的方法，该衍生物可用作药物，用于制备药物的中间体，以及制备中间体的方法。
• Substituted azetidinyl compounds as GlyT1 inhibitors
  申请人：DART NEUROSCIENCE (CAYMAN) LTD.

  公开号：US10040759B2

  公开（公告）日：2018-08-07

  The invention provides a chemical entity of Formula (I) wherein R1, R2, R3, R4, X, and Y have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by GlyT1 activity; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training, including animal skill training; and treating other disorders, including pain and alcohol-dependence.

  本发明提供了式(I)的化学实体，其中 R1、R2、R3、R4、X 和 Y 具有本文所述的任一值，还提供了包含这种化学实体的组合物；制造它们的方法；以及它们在多种方法中的用途，包括代谢和反应动力学研究；检测和成像技术；放射性治疗；调节和治疗由 GlyT1 活性介导的疾病；治疗神经系统疾病、中枢神经系统疾病、痴呆症、神经退行性疾病和创伤依赖性功能丧失；治疗中风，包括中风康复期间的认知和运动障碍；促进神经保护和神经恢复；提高认知和运动训练的效率，包括动物技能训练；以及治疗其他疾病，包括疼痛和酒精依赖。
• Diaryl substituted 6,5-fused ring compounds as C5aR inhibitors
  申请人：CHEMOCENTRYX, INC.

  公开号：US10828285B2

  公开（公告）日：2020-11-10

  The present disclosure provides, inter alia, Compounds of Formula (I) or pharmaceutically acceptable salts thereof that are modulators of the C5a receptor. Also provided are pharmaceutical compositions and methods of use including the treatment of diseases or disorders involving pathologic activation from C5a and non-pharmaceutical applications.

  本公开特别提供了式 (I) 化合物 或其药学上可接受的盐，它们是 C5a 受体的调节剂。此外，还提供了药物组合物和使用方法，包括治疗涉及 C5a 病理激活的疾病或失调以及非药物应用。
• Method for producing benzimidazole derivative
  申请人：Sumitomo Dainippon Pharma Co., Ltd.

  公开号：US11242332B2

  公开（公告）日：2022-02-08

  The present invention relates to a process to prepare a benzimidazole derivative useful as a medicament, an intermediate for preparing the medicament, and a process to prepare the intermediate.

  本发明涉及一种制备用作药物的苯并咪唑衍生物的工艺、一种制备该药物的中间体以及一种制备该中间体的工艺。